EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Randomisierte kontrollierte StudieOpen Access

Direct-Acting Antivirals Quickly Eradicate Hepatitis C Virus From the Liver in People With Human Immunodeficiency Virus but Do Not Fully Reverse Immune Activation

Jaiprasath Sachithanandham, Julia Leep-Lazar, Jeffrey Quinn, Kenneth Bowden, Prasanthy Balasubramaniam, Kathleen Ward, Ruy M Ribeiro, Mark S Sulkowski, Ashwin Balagopal iD

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiae598 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Jaiprasath Sachithanandham und 8 weiteren Autor:innen. Beteiligte Einrichtung: W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University School of Public Health, Baltimore, Maryland. Hauptthemen laut MEDLINE: Antiviral Agents, Hepacivirus, Hepatitis C, Hepatitis C, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatitis C virus (HCV) infects nearly one-fourth of people with human immunodeficiency virus (HIV). The role of direct-acting antivirals (DAAs) on immune activation in people with HIV (PWH) and HCV is poorly understood.

Methods

We quantified plasma HCV RNA and CXCL10 in persons with HCV monoinfection versus HIV/HCV coinfection receiving sofosbuvir-velpatasvir. Single-cell laser capture microdissection was applied to liver biopsies obtained before and within 4–7 days of DAA initiation to estimate HCV clearance and changes in interferon-stimulated genes (ISGs).

Results

We enrolled 10 people with chronic genotype 1a HCV: 5 were PWH with ART-suppressed viremia and CD4+ T cell counts >200 cells/µL. First- and second-phase plasma HCV RNA kinetics were not different between groups. Median (min–max) proportions of infected hepatocytes at biopsy 1 were 0.06 (0.01–0.59) in HCV monoinfection and 0.21 (0.04–0.87) in HIV/HCV coinfection and did not differ. Participants had lower intracellular HCV RNA levels at biopsy 2. CXCL10 levels declined in both groups but were higher in coinfection than in monoinfection even at the end of treatment. The proportion of cells expressing ISGs diminished in monoinfection but increased in coinfection.

Conclusions

Whereas DAAs rapidly cleared intrahepatic HCV in both groups, immune activation was slower to diminish in PWH. Residual immune activation in PWH warrants further exploration. Clinical Trials Registration. NCT02938013.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepacivirusHepatitis CHepatitis C, ChronicHIV InfectionsLiverAdultFemaleHumansMaleMiddle AgedCarbamatesChemokine CXCL10CoinfectionHeterocyclic Compounds, 4 or More RingsRNA, ViralSofosbuvirViral LoadBenzimidazolesBenzopyrans

Stichwörter der Autor:innen

HIV/HCV coinfectiondirect-acting antiviralsimmune activationsingle-cell laser capture microdissectionviral kinetics

Substanzen

Antiviral AgentsCarbamatesChemokine CXCL10CXCL10 protein, humanHeterocyclic Compounds, 4 or More RingsRNA, ViralSofosbuvirvelpatasvirBenzimidazolesBenzopyrans

Autor:innen und Institutionen

  • W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University School of Public Health, Baltimore, Maryland.
  • Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania.
  • Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore.
  • Applied Physics Laboratory, Johns Hopkins University, Laurel, Maryland.
  • Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico.

ORCID-Profile: Ashwin Balagopal

Förderung

  • NIDA NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Sachithanandham, J., Leep-Lazar, J., Quinn, J., Bowden, K., Balasubramaniam, P., Ward, K., Ribeiro, R. M., Sulkowski, M. S., & Balagopal, A. (2025). Direct-Acting Antivirals Quickly Eradicate Hepatitis C Virus From the Liver in People With Human Immunodeficiency Virus but Do Not Fully Reverse Immune Activation. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae598

Vancouver

Sachithanandham J, Leep-Lazar J, Quinn J, Bowden K, Balasubramaniam P, Ward K, et al. Direct-Acting Antivirals Quickly Eradicate Hepatitis C Virus From the Liver in People With Human Immunodeficiency Virus but Do Not Fully Reverse Immune Activation. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae598

BibTeX
@article{Sachithanandham2025,
  author = {Sachithanandham, Jaiprasath and Leep-Lazar, Julia and Quinn, Jeffrey and Bowden, Kenneth and Balasubramaniam, Prasanthy and Ward, Kathleen and Ribeiro, Ruy M and Sulkowski, Mark S and Balagopal, Ashwin},
  title = {Direct-Acting Antivirals Quickly Eradicate Hepatitis C Virus From the Liver in People With Human Immunodeficiency Virus but Do Not Fully Reverse Immune Activation},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiae598}
}
Kostenlos starten →